The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 1,601–1,700 of 2,716
Salivary Cortisol Predicts Cardiovascular Mortality
Pahuja, R., & Kotchen, T. A. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0220-0 · Cited by 4
Measuring cortisol levels in hair: potential clinical applications in Cushing’s syndrome
van Rossum, E. F., Manenschijn, L., & Feelders, R. A. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.95 · Cited by 4
Miller, A. H., & Yeung, S. J. (2016) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2015.06.084 · Cited by 4
Żukowski, Ł., Myśliwiec, J., & Górska, M. (2013) · Endokrynologia Polska · doi:10.5603/ep.2013.0003 · Cited by 5
“DST was performed typically by measurement of serum cortisol in morning sample (8am) after administration of 1 mg dexamethasone at 11pm the previous night.”
BackgroundInfluentialSpecial Aspects of Cushing’s Syndrome: Pregnancy
Abdelmannan, D. K., & Aron, D. C. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-449-4_21 · Cited by 5
Kuzu, İ., Zuhur, S. S., Demir, N., Aktas, G., Öztürk, F. Y., & Altuntaş, Y. (2016) · Endokrynologia Polska · doi:10.5603/ep.a2016.0028 · Cited by 7
“However, there are still deliberations on the cut-off value of test positivity [1, 7, 22, 27].”
BackgroundMeasurement of Glucocorticoids in Biological Fluids
Owen, L. J. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-616-0_12 · Cited by 4
Síndrome de Cushing ectópico: revisión de la literatura
Gutiérrez-Restrepo, J., & Román-Gonzaléz, A. (2016) · Revista Colombiana de Cancerología · doi:10.1016/j.rccan.2016.03.001 · Cited by 10
Syndrome of ectopic ACTH secretion in a patient without a verified tumor
Ershova, E. V., Senyushkina, E. S., & Troshina, E. A. (2018) · Obesity and metabolism · doi:10.14341/omet9402 · Cited by 4
Tsurutani, Y., Miyoshi, K., Inoue, K., Takiguchi, T., Saito, J., Omura, M., & Nishikawa, T. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0445 · Cited by 4
Sandner, B., & Kratzsch, J. (2017) · Journal of Laboratory Medicine · doi:10.1515/labmed-2017-0024 · Cited by 4
Juszczak, A., Morris, D. G., Grossman, A. B., & Nieman, L. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00013-5 · Cited by 7
Self-citationNewell-Price, J. D. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00017-9 · Cited by 9
Self-citationDisorders of the adrenal cortex and medulla
Alter, D. N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815499-1.00041-7 · Cited by 4
Sato, H., Imamura, Y., Sakamoto, S., Sugiura, M., Arai, T., Yamamoto, S., Takeuchi, N., Sazuka, T., Nakamura, K., Nagano, H., et al. (2020) · International Journal of Urology · doi:10.1111/iju.14445 · Cited by 6
Daniel, E., & Newell-Price, J. D. C. (2017) · Medicine · doi:10.1016/j.mpmed.2017.05.007 · Cited by 9
Self-citation[Screening for Cushing's syndrome in obese patients; is it really necessary?].
Expósito, M. R. A., Tenorio-Jiménez, C., Puerta, M. J. M., García, G. M., Sánchez, I. P., Jiménez, C. M., & Moreno, M. Á. G. (2014) · PubMed · doi:10.3305/nh.2014.29.5.7256 · Cited by 4
Carmichael, J. D., Zada, G., & Selman, W. R. (2015) · Neurosurgical FOCUS · doi:10.3171/2014.11.focus14778 · Cited by 4
Jones, S. C., Nutter, S., & Saunders, J. F. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02580-5 · Cited by 3
“Although researchers have documented the clinical presentation of Cushing’s, [7] approaches to working with patients with a possible diagnosis, [1] as well as treatment approaches and outcomes, [17, 18] there is an absence of research on the lived experience of patients with Cushing’s in healthcare.”
BackgroundCharchar, H. L. S., Alencar, G. A., Mariani, B. M. P., Kuhn, A. W., Silva, J. T. D. C., Bouys, L., Vaduva, P., Nishi, M. Y., Ledesma, F. L., Almeida, M. Q., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf465 · Cited by 4
Soliman, A. R., Ahmed, R. M., Meligi, A. A. H. E., Abo-Zeid, A. G., Amer, M. A., Atef, A., Yousry, A., Saleh, A. A., Fahmy, E. M., Makar, W., et al. (2025) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-025-00513-x · Cited by 3
“So , if the 1 mg ONDST is positive, urinary-free cortisol (UFC) or midnight serum or salivary cortisol is measured to confirm or rule out the diagnosis [19, 20].”
Castro, M. A., Gómez, A. C., Rosillo, M., Rodríguez, A., Madrid, I., Corrales, E. P., & Cano, A. M. G. (2025) · Clinical Endocrinology · doi:10.1111/cen.70065 · Cited by 6
Alcubierre, D. D., Ferrari, D., Tomaselli, A., Moscucci, F., Bonaventura, I., Francia, A. L., Vozza, E., Lospinuso, I., Ettorre, E., Hasenmajer, V., et al. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag018 · Cited by 6
Özaydın, D., Vergili, E., Kaya, A., Demir, A. N., Kadıoğlu, P., & Tanrıöver, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1759071 · Cited by 3
“Cushing ’ s disease was diagnosed in patients with clinical features of hypercortisolism accompanied by abnormal cortisol suppression testing and elevated adrenocorticotropic hormone (ACTH) levels (13, 14).”
Bandeira, D. B., Santos, G. D. A., Glezer, A., Machado, M. C., Boguszewski, C. L., & Nogueira, V. D. S. N. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10016-x · Cited by 5
“with the criteria outlined in current clinical guidelines [1, 19 ].”
Natural history of large adrenal tumors
Macech, M., Stępień, M., Podgórska, J., Toutounchi, S., Koperski, Ł., Barankiewicz, J., Bobrowicz, M., Kondracka, A., & Ambroziak, U. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1774131 · Cited by 3
Morbidität und Mortalität beim Cushing-Syndrom
Vogel, F., Braun, L., & Reincke, M. (2021) · Der Internist · doi:10.1007/s00108-021-01222-7 · Cited by 4
“Diagnosealgorithmusbeibegründetem Verdacht auf ein Cushing-Syndrom (modifiziert nach [12])”
BackgroundEndocrine and metabolic complications of advanced cancer
Ryan, R., & Casey, R. T. (2021) · doi:10.1093/med/9780198821328.003.0084 · Cited by 3
Garstka, N., & Remzi, M. (2022) · Current Opinion in Urology · doi:10.1097/mou.0000000000001050 · Cited by 3
“The guidelines of the Endocrine Society and American Association of Clinical Endocrinologists/American Association of Endocrine Surgeons additionally recommend to determine the baseline serum dehydroepiandrosterone sulfat (DHEAS) [5,17].”
BackgroundInfluentialBilateral inferior petrosal sinus sampling: Procedural data from a German single-center study
Augustin, A. M., Detomas, M., Hartung, V., Thurner, A., Tröger, V., Deutschbein, T., & Kickuth, R. (2023) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/a-2083-9942 · Cited by 3
“Bilateral inferior petrosal sinus sampling (BIPSS) is a minimally invasive procedure, considered the gold standard for distinguishing CD from ECS by measuring the pituitary hormone output directly [6, 7].”
BackgroundMethodAn Integrated Clinical Score to Predict Remission in Cushing’s Disease
Gupta, N., Dutta, A., Baruah, M. M., Bhansali, A. K., Ahuja, C. K., Dhandapani, S., Bhadada, S. K., Saikia, U. N., & Walia, R. (2023) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_314_23 · Cited by 3
“[19] Until 2009, in-house radioimmunoassay (RIA) was used for measuring ACTH and cortisol, and electro-chemiluminescence immunoassay (Roche Diagnostic, Germany) was used after that.”
MethodAlsarari, A. A., Abdulkader, A. A., Farooqi, W. A., Al-Shibani, S. K., & Khuwaitir, T. S. A. (2024) · Cureus · doi:10.7759/cureus.56434 · Cited by 3
“Features of Cushing’s syndrome (moon face, buffalo hump, central obesity hypertension, fragile skin, easy bruising, fatigue, muscle weakness) are due to high blood cortisol levels [7].”
BackgroundSadhwani, N., Bora, S. K., Deepa, S., Katiyar, V., Raheja, A., Garg, A. K., Suri, V. S., Tandon, N., Sharma, M. C., Khadgawat, R., et al. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.05.014 · Cited by 3
Ballerini, M. G., Freire, A. V., Rodríguez, M. E., Brenzoni, L., Daga, L., Castro, L., Cau, A. C. A., Testa, G., Gil, M. R., Braslavsky, D. G., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000540785 · Cited by 3
“…CS have been reported using reference liquid chromatography-tandem mass spectrometry in adults (nSC > 4 nmol/L) and in children (nSC > 2.4 nmol/ L) [2, 7, 26], the latter obtained with very few index cases of Cushing ’ s disease and a cohort of children with obesity from an outpatient clinic [7].”
InfluentialImproving the radiological prediction of surgical resection of nonfunctioning pituitary adenomas
Giardini, E., Barbosa, M. Á., Ventura, N., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02479-z · Cited by 3
“IGF-I and prolactin (diluted 1:100 in adenomas ≥ 3 cm in the largest diameter to exclude hook effect) were mea - sured for all patients, and during suspicion of Cushing’s disease, tests were performed to investigate hypercortisolism, as recommended in the most recent guidelines [19–21].”
Vage, A., Gormley, G., & Hamilton, P. (2024) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632241301618 · Cited by 4
Mansour, N., Brüdgam, D., Heinrich, D. A., Dischinger, U., Reisch, N., Völter, F., Stüfchen, I., Nowak, E., Zopp, S., Vasileva, V., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1521680 · Cited by 7
Rege, J., & Udager, A. M. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106666 · Cited by 3
Balsak, B. Ö. T., İmga, N. N., Polat, Ş. B., Aydin, C., Topaloğlu, O., Ersoy, R., & Çakır, B. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2455373 · Cited by 4
“When clinical suspicion arises, evaluation of autonomous cortisol secretion becomes imperative [4,5].”
Co-existing autonomous cortisol secretion in primary aldosteronism
Barlas, T., Altınova, A. E., Törüner, F. B., Cerit, E. T., Yalçın, M. M., Karakoç, M. A., & Aktürk, M. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.101706 · Cited by 3
Ferraù, F., Alessi, Y., Nista, F., Roux, A., Ferone, D., & Arvat, E. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02537-0 · Cited by 4
Hair Cortisone Levels and the Metabolic Syndrome: Stronger Links in Younger Compared to Older Adults
Kuckuck, S., Lengton, R., März, J., van Gerwen, N., Rizopoulos, D., Hillegers, M. H. J., Kavousi, M., van den Berg, S. A. A., Giltay, E. J., Penninx, B. W. J. H., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf322 · Cited by 2
The Evolution of Our Understanding of the Nuances of Pathologic Cortisol Secretion
Blevins, L. S. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.002 · Cited by 4
Katabami, T., Matsuba, R., Nagasaka, T., Yamamoto, Y., Sakai, K., & Sone, M. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0696 · Cited by 3
Sprenkeler, V. E., van Herwaarden, A. E., van de Ven, A. C., Küsters, B., Jenniskens, S. F. M., Netea-Maier, R. T., & de Laat, J. M. (2025) · Journal of Neuroendocrinology · doi:10.1111/jne.70066 · Cited by 2
Chacko, S. R., Sharma, S. S., Ahmadian, S., Saini, J., Fell, V. M., Peersen, A. F., Atkinson, E. J., Gruber, L., Gompel, J. J. V., Simha, V., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf693 · Cited by 3
Witek, P., Zieliński, G., & Szamotulska, K. (2015) · International Journal of Endocrinology · doi:10.1155/2015/357165 · Cited by 4
“Thediagnostic criteria of CD and the treatment principles in typical cases have been established according to a consensus of experts [1, 2].”
The Endocrine Society Clinical Practice Guidelines: A Self-Assessment
Vigersky, R. A., Bhasin, S., & Martin, K. A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2300 · Cited by 3
Topiramate as a Cause of False Positive in the Overnight 1-Mg Dexamethasone Suppression Test
Capel, I., Giménez‐Palop, O., Subías, D., & Rigla, M. (2014) · Endocrine Practice · doi:10.4158/ep13485.cr · Cited by 3
Endocrine and Metabolic Symptoms of Cancer and Its Treatment
Dev, R. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1225-1_13 · Cited by 3
Cushing's disease: establishing the diagnosis and management approach.
Varadhan, L., Aror, A., Walker, A. B., & Varughese, G. I. (2013) · PubMed · Cited by 4
Late diagnosis of Cushing’s disease in a child: what lessons can be learned?1)
Gust, D. A., & Gordon, T. P. (2012) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2012-0043 · Cited by 3
Screening for Cushing's syndrome in an era of epidemic obesity.
Clutter, W. E. (2011) · Missouri medicine · Cited by 3
Multimodal Assessment of Pituitary and Parasellar Lesions
Vaughan, T. B., Blevins, L. S., Vaphiades, M. S., & Wand, G. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6839-6.10016-4 · Cited by 3
Turcu, A. F., & Auchus, R. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-45950-9_10 · Cited by 4
Tirosh, A., Lodish, M. B., Lyssikatos, C., Belyavskaya, E., Papadakis, G. Z., & Stratakis, C. A. (2017) · Hormone Research in Paediatrics · doi:10.1159/000464463 · Cited by 5
Losing My Mind: An Uncommon Presentation of Cushing’s Disease
Tan, A. T. H., Wong, Y. L. J., & Soo, S. C. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.07.045 · Cited by 3
Atar, R. V., Yildiz, I., Topcu, B., Elbuken, G., & Zuhur, S. S. (2020) · Northern Clinics of Istanbul · doi:10.14744/nci.2019.54771 · Cited by 7
“8 μg/dl, as recommended by the recent Endocrine Society and the European Society for Endocrinology’s clinical practice guidelines [7, 12].”
BackgroundMethodInfluentialEndocrine Disturbances Affecting Reproduction
Chang, A. Y., & Auchus, R. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2758-2.00025-1 · Cited by 3
Pituitary Dysfunction as a Cause of Cardiovascular Disease
Gogakos, A. I., Gogakos, T., Kita, M. D., & Efstathiadou, Z. A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612824999201105165351 · Cited by 3
Winzinger, E. P., Jandíková, H., Haase, M., Knauerhase, A., Winzinger, T., Schott, M., & Willenberg, H. S. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1539-6442 · Cited by 3
“Therefore, instead of relying on the classical determination of hormone concentrations it is increasingly discussed to take into account aspects of the case histories and the results of the clinical examination [5, 18].”
BackgroundPresurgical predictive factors of surgical remission in Cushing's disease. Study of 32 cases
Castro, M. A., Pinedo, M. M., Fernández-Argüeso, M., Pérez, M. P., Ruiz, E. B., Pian, H. G., Berrocal, V. R., & Corrales, E. P. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.07.004 · Cited by 5
Characterization of a paradoxical post-operative increase in serum cortisol in Cushing disease
Catalino, M. P., Gelinne, A. M., Ironside, N. T., Coley, J., Jonas, R. H., Kearns, K. N., Munoz, A. R., Montaser, A. S., Vance, M. L., Jane, J. A., et al. (2022) · Pituitary · doi:10.1007/s11102-021-01203-x · Cited by 3
“The diagnosis of Cushing syndrome was based on typical signs and symptoms of hypercortisolemia and at least two abnormal laboratory tests: elevation of 24-h urine free cortisol, elevation of late-night salivary cortisol levels, or failed cortisol suppression after 1 mg of dexamethasone [24].”
MethodStressing the need for validated measures of cortisol in HIV research: A scoping review
Swann, S. A., King, E. M., Côté, H. C. F., & Murray, M. C. M. (2022) · HIV Medicine · doi:10.1111/hiv.13272 · Cited by 6
“However, it should be noted that measuring cortisol in the afternoon is not aligned with clinical standards [37].”
BackgroundFlippo, C. L., Tatsi, C., Sinaii, N., Sierra, M. D. L. L., Belyavskaya, E., Lyssikatos, C., Keil, M. F., Spanakis, E. K., & Stratakis, C. A. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac053 · Cited by 4
Lodish, M. B., Keil, M. F., & Stratakis, C. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-73782-9_15 · Cited by 5
Takenouchi, H., Anno, T., Iwamoto, H., Takahashi, K., Iwamoto, Y., Horiya, M., Kimura, Y., Kawasaki, F., Kaku, K., Tomoda, K., et al. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8665-21 · Cited by 5
“Why there are so few reports of aortic dissection complicated with Cushing’s disease remains unclear, although it is considered that Cushing’s disease accounts for a large proportion of Cushing’s syndrome cases (16).”
BackgroundSensitive and Robust LC-MS/MS Analysis of Salivary Cortisol in Negative Mode
Anderson, W. B., Gqamana, P. P., & Zhang, Y. V. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2565-1_10 · Cited by 3
Baldane, S., Celik, M., Kebapçılar, L., İpekçi, S. H., Abuşoğlu, S., Yılmaz, H., & Alptekin, H. (2022) · Endocrine Regulations · doi:10.2478/enr-2022-0028 · Cited by 3
Overview of endocrine hypertension in children
Metwalley, K. A., & Farghaly, H. S. (2022) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2022.101581 · Cited by 3
Neutrophilia with subclinical Cushing’s disease: A case report and literature review
Zhang, Y., Lin, X., Liu, F., Shou, S., & Jin, H. (2023) · Open Life Sciences · doi:10.1515/biol-2022-0540 · Cited by 3
“as well as high blood pressure, blood sugar, cholesterol, and triglycerides [13,14].”
BackgroundArdakani, M. A. T., Rabizadeh, S., Yadegar, A., Mohammadi, F., Reyhan, S. K., Qahremani, R., Ghanaati, H., Esteghamati, A., & Nakhjavani, M. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01495-z · Cited by 3
“Almost all cases of ACTH-dependent are due to pituitary adenoma (Cushing’s disease) or EAS [1, 2, 6].”
BackgroundResultInfluentialDiagnostic performance of an automated immunoassay for salivary cortisol
Laguillier, C., Bonnet-Serrano, F., Leguy, M.-C., Simeonovic, M., Sée, C., Zientek, C., Soussan, M., Bouys, L., Bertherat, J. Y., & Guibourdenche, J. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.10.007 · Cited by 6
Obesity-Related Hemodynamic Alterations in Patients with Cushing’s Disease
Jurek, A., Krzesiński, P., Uziębło‐Życzkowska, B., Witek, P., Zieliński, G., Wierzbowski, R., Kazimierczak, A., Banak, M., & Gielerak, G. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061658 · Cited by 4
Seco-Cervera, M., Ibáñez-Cabellos, J. S., Pallardó, F. V., García‐Giménez, J. L., Aulinas, A., Martel‐Duguech, L., Webb, S. M., & Valassi, E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1410080 · Cited by 3
Finding the Culprit: Cushing Syndrome Secondary to Lung Carcinoid Tumor
Vaca, R., & Shah, N. A. (2024) · AACE Clinical Case Reports · doi:10.1016/j.aace.2024.09.002 · Cited by 6
USP8 Mutations Associated with Cushing’s Disease Alter Protein Structure Dynamics
Petukhova, N. V., Poluzerova, A., Bug, D. S., Nerubenko, E., Kostareva, A. A., Tsoy, U. A., & Dmitrieva, R. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312697 · Cited by 3
Rubio, A., Tofé, S., Elorza, M. Á., Asis, S. S., Pastor, M., Delgado, J. A., & Barceló, A. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120129 · Cited by 3
Rare Adrenal Tumors and Adrenal Metastasis
Leonard, S., & Smaldone, M. C. (2025) · Urologic Clinics of North America · doi:10.1016/j.ucl.2025.01.010 · Cited by 4
Cushing´s syndrome: twenty-five years of clinical experience in Navarre
García, L. P., Anda, E., & Rojo, J. (2012) · Anales del Sistema Sanitario de Navarra · doi:10.4321/s1137-66272012000300012 · Cited by 4
Síndrome de Cushing iatrogénico por corticoides inhalados en paciente VIH
Frías, A., Ortiz, A., Soto, M., Muñoz, F., & Chacón, C. (2016) · Revista médica de Chile · doi:10.4067/s0034-98872016000700016 · Cited by 4
Making the Diagnosis: Laboratory Testing and Imaging Studies
Nieman, L. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804340-0.00005-x · Cited by 3
Self-citationIs the new treatment for Cushing's disease too sweet?
Grossman, A. B. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30341-8 · Cited by 3
Systemic Vasculitis: An Important and Underestimated Cause of Malignant Hypertension
Zhu, Q., Liu, S., Heizhati, M., et al. (2019) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2019.0009 · Cited by 3
Inder, W. J., & Jang, C. (2021) · Australian Journal of General Practice · doi:10.31128/ajgp-10-20-5688 · Cited by 4
Mohan, A., Tijmes, S., Cohen, J., Sherman, E. M., & Eckardt, P. (2021) · Pain Management · doi:10.2217/pmt-2020-0101 · Cited by 3
Lower hair cortisol among patients with sickle cell disease may indicate decreased adrenal reserves.
Hollister, B. M., Zilbermint, M. F., Minniti, C. P., Buscetta, A. J., Abdallah, K. E., You, S., Soldin, S. J., Meyer, J. S., Stratakis, C. A., & Bonham, V. L. (2021) · American Journal of Blood Research · Cited by 4
Dalmazi, G. D., Morandi, L., Rubin, B., Pilon, C., Asioli, S., Vicennati, V., De Leo, A., Ambrosi, F., Santini, D., Pagotto, U., et al. (2021) · Yearbook of pediatric endocrinology · doi:10.1530/ey.18.8.14 · Cited by 3
Yener, S., Tuna, G., Kant, M., Akış, M., Kara, Ö., Kalas, B., Barış, M., & İşlekel, H. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1661-4126 · Cited by 3
“These tests depend on the measurement of cortisol passively diffusing into the acinar cells of the salivary glands or being filtered in the renal glomerulus [10, 23].”
BackgroundKlein, J., Vuguin, P. M., & Hyman, S. J. (2014) · Pediatrics in Review · doi:10.1542/pir.35.9.405 · Cited by 3
Association of DNA methylation with steroidogenic enzymes in Cushing’s adenoma
Kodama, T., Oki, K., Otagaki, Y., Baba, R., Okada, A., Itcho, K., Kobuke, K., Nagano, G., Ohno, H., Hinata, N., et al. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0115 · Cited by 3
Systematic approach to the diagnosis and management of endocrine hypertension
Stowasser, M., Jansen, P. M., & Wolley, M. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-96120-2.00009-1 · Cited by 6
Dexamethasone-suppressed corticotropin-releasing hormone stimulation test in morbid obese adults
Saiegh, L., Keren, D., Rainis, T., Sheikh‐Ahmad, M., Reut, M., Nakhleh, A., Wirsansky, I., Chen‐Konak, L., Schiff, E., & Shechner, C. (2015) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2015.07.004 · Cited by 3
“Therefore, currently this test is utilised to confirm or rule out CS when other and more technically simple screening tests are non-conclusive [3].”
BackgroundMethodInfluentialAssessment of the Obese Patient
Bessesen, D. H. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1203-2_12 · Cited by 3
“The Endocrine Society has published a Clinical Practice Guideline on the diagnosis of Cushing’s syndrome [ 75 ].”
MethodEarly recognition of Cushing's disease: A case study
Iuliano, S. L., & Laws, E. R. (2013) · Journal of the American Association of Nurse Practitioners · doi:10.1111/1745-7599.12014 · Cited by 3
“National guidelines recommend a logical series of diagnostic testing for diagnosing Cushing’s disease, beginning with the demonstration of elevated blood, urinary and salivary cortisol levels (Table 2; Nieman et al., 2008).”
BackgroundCarey, R. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2162 · Cited by 3
Adenomas hipofisarios no funcionantes
Andújar, P., Fernández-Rodríguez, E., Bernabéu, I., et al. (2012) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(12)70379-7 · Cited by 3
Adrenal Disorders in Rheumatology
Ormseth, M. J., & Sergent, J. S. (2010) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2010.09.005 · Cited by 3
Laparoscopic adrenalectomy for co-secreting aldosterone and cortisol adenomas
Lobo, C., Kolinioti, A., Hainsworth, A. J., Bano, G., Mudan, S., & Sharma, A. D. (2012) · International Journal of Surgery · doi:10.1016/j.ijsu.2012.08.017 · Cited by 3
Reduction of blood pressure in patients with treatment-resistant hypertension
Acelajado, M. C., Calhoun, D. A., & Oparil, S. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903379552 · Cited by 3
“These include measuring plasma metanephrines to screen for pheochromocytoma, documenting cortisol excess or nonsuppression to screen for Cushing’s syndrome (via any of the following: urine cortisol, late-night salivary cortisol, or 1 mg overnight or 2 mg 48-h dexamethasone suppression test [42]), measuring parathyroid…”
Method
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.